Moving from opacity to transparency in pharmaceutical policy.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed.

1. Transparency in public pharmaceutical sector: the key informants' perceptions from a developing country.BMC health services research · 2021
   Article
2. Mechanisms for addressing and managing the influence of corporations on public health policy, research and practice: a scoping review.BMJ open · 2020
   Article
3. A New Decision Model Approach for Health Technology Assessment and A Case Study for Dialysis Alternatives in Turkey.International journal of environmental research and public health · 2020
   Article
4. Regulating prescription drugs for patient safety: does Bill C-17 go far enough?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2014
   Review
5. Use of product listing agreements by Canadian provincial drug benefit plans.Healthcare policy = Politiques de sante · 2013
   Article
6. The timing of drug funding announcements relative to elections: a case study involving dementia medications.PloS one · 2013
   Article
7. Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.Cost effectiveness and resource allocation : C/E · 2012
   Article
8. Unlocking Health Canada's cache of trade secrets: mandatory disclosure of clinical trial results.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2012
   Article
9. Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.BMC health services research · 2011
   Article
10. Will Open Government make Canada's health agencies more transparent?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2011
    Article
11. Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decision-making framework to growth hormone for Turner syndrome patients.Cost effectiveness and resource allocation : C/E · 2010
    Article
12. Cost shifting and timeliness of drug formulary decisions in atlantic Canada.Healthcare policy = Politiques de sante · 2010
    Article
13. The power of "principles" in a national pharmaceuticals strategy.Healthcare policy = Politiques de sante · 2009
    Article
14. Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.BMC health services research · 2008
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as